Hims & Hers Partners With Eli Lilly to Offer Branded Weight-Loss Medications
Article excerpt
Highlighted: the sentence this signal was extracted from
Hims & Hers has partnered with Eli Lilly to offer the pharmaceutical company's FDA-approved obesity treatments directly through its digital health platform. The agreement allows eligible patients to access Lilly's injectable Zepbound (tirzepatide) and oral Foundayo (orforglipron) through Hims & Hers, expanding access to branded GLP-1 medications without requiring patients to navigate separate prescription or purchasing platforms. Under the partnership, Hims & Hers pharmacies will receive direct access to Lilly's medications at self-pay prices. Patients can complete a virtual consultation, receive a prescription when clinically appropriate and arrange home delivery through a single platform. Monthly self-pay pricing starts at $149 for Foundayo and $299 for Zepbound, providing patients with transparent pricing options for FDA-approved weight-loss treatments. The integration builds on Hims & Hers' existing weight management services, which include ongoing clinical support, nutrition guidance, regular check-ins and access to a patient community. By combining medication access with virtual care and behavioral support, the company aims to provide a more comprehensive weight management experience while simplifying the treatment journey. The agreement follows a similar partnership with Novo Nordisk, which began offering its branded Wegovy and Ozempic medications through Hims & Hers...
Keep reading with a free account
The rest of this article, and every signal for Hims & Hers, is in your free account.